Skip to content
DraconiticResearch
Search Sources API
203,952 studies31 sourcesUpdated 8 min ago
Peer-reviewedCC BYBMJ Open

Cohort profile: Penile Cancer Data Base Sweden (PenCBaSe) V.2.0

  • Kimia Kohestani1,2
  • Axel Gerdtsson3,4,5
  • Dominik Glombik6
  • Sinja Kristiansen7
  • Mats Lambe8
  • Jenny Magnusson1,2
  • Per Nordlund9
  • Erik Persson10
  • Henrik Ugge6,11
  • Peter Kirrander6
11 affiliations
  1. 1Department of Urology, Sahlgrenska University Hospital, Gothenburg, Västra Götaland County, Sweden
  2. 2Department of Urology, University of Gothenburg Institute of Clinical Sciences, Gothenburg, Västra Götaland County, Sweden
  3. 3Department of Urology, Skåne University Hospital, Malmö, Sweden
  4. 4Department of Translational Medicine, Lund University, Lund, Sweden
  5. 5Division of Urology, Karolinska Institutet, Stockholm, Sweden
  6. 6Department of Urology, Örebro University, Örebro, Sweden
  7. 7Department of Dermatology and Venereology, Lund University, Lund, Sweden
  8. 8Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
  9. 9Department of Urology, Södersjukhuset, Stockholm, Stockholm County, Sweden
  10. 10Regional Cancer Centre Central Sweden, Uppsala, Sweden
  11. 11School of Medical Sciences, Örebro University, Örebro, Sweden
Read full textDOICite

Abstract

Purpose Penile Cancer Data Base Sweden (PenCBaSe) V.2.0 is an update of PenCBaSe V.1.0, which was established in 2013 to address a wide range of epidemiological research questions in a population-based cohort of men with penile cancer.The study population in PenCBaSe V.2.0 was defined by 3883 cases of penile intraepithelial neoplasia (PeIN) or penile cancer registered in the National Penile Cancer Register (NPECR).Participants PenCBaSe V.2.0 includes 3883 cases of PeIN or penile cancer registered in the NPECR between 2000 and 2023 and two separate comparison cohorts with 38 448 comparators free from PeIN or penile cancer matched on birth year, sex and region of residence. The median age at inclusion was 69 years (range 18–101).Findings to date The database contains register-based information collected from standardised forms in the NPECR on diagnostic evaluation, tumour characteristics, primary treatment, lymph node management, postoperative complications and follow-up with high completeness (95% between 2000 and 2023) and validity. Moreover, by means of record linkage to six national healthcare and sociodemographic registers, data on socioeconomic factors, comorbidity and patterns of filings of prescribed drugs are available. The comorbidity burden was lower in the comparison cohort.Future plans PenCBaSe V.2.0 will be used to investigate a multitude of research questions within three principal domains: socioeconomic status and demographic factors, risk factors for disease and stage, respectively treatment-related outcomes and complications. The steering committee of PenCBaSe welcomes new collaborations. For more information, please contact the chairman of the steering committee of PenCBaSe (https://cancercentrum.se/diagnosbehandling/cancerdiagnoser/penis/kvalitetsregister.3518.html).

Related

  1. Cohort profile: detailed characteristics of patients with first-time acute pancreatitis in a 10-year single centre consecutive cohort in southern Sweden (DeCAP)
    Caroline Bjarnevik, Martina Sjöbeck, Natalia Sande +3
    BMJ OpenPeer-reviewedCC BY-NC 4.0Full textSurgery & anaesthesiaCrossrefEurope PMC
  2. Academic achievements among siblings of children with cancer in Sweden: a nationwide register-based cohort study
    Moa Carlbaum, Yishan Liu, Jan Sundquist +2
    Frontiers in Public HealthPeer-reviewedCC BY 4.0Full textObstetrics, gynaecology & paediatricsCrossrefDOAJ
  3. Cohort profile: the Prostate-Specific Antigen Cohort (PSA Cohort) and the Prostate Cancer Risk Cohort (ProCaRis Cohort) - cohorts based on Danish health data
    Susanne Hamborg Larsen, Jacob Hesselvig Fredsøe, Thomas Bøjer Rasmussen +4
    BMJ OpenPeer-reviewedCC BY-NC 4.0Full textGeneral medicineCrossref
  4. MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis
    Jia-Yao Wang, Yan-Xiang Shao, Li-Li Yang +6
    Future OncologyPeer-reviewedLicence not statedFull textSurgery & anaesthesiaPMC
  5. Filling the information gap: a validated comparison of ChatGPT, Gemini, and Claude for penile cancer patient education
    Jeffery Yang, Ymer Bushati, Sarah Lorger +2
    Translational andrology and urologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{kohestani2026cohort,
  title = {{Cohort profile: Penile Cancer Data Base Sweden (PenCBaSe) V.2.0}},
  author = {Kimia Kohestani and Axel Gerdtsson and Dominik Glombik and Sinja Kristiansen and Mats Lambe and Jenny Magnusson and Per Nordlund and Erik Persson and Henrik Ugge and Peter Kirrander},
  journal = {BMJ Open},
  year = {2026},
  month = nov,
  doi = {10.1136/bmjopen-2026-122591},
  url = {https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-122591},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Cohort profile: Penile Cancer Data Base Sweden (PenCBaSe) V.2.0
AU  - Kimia Kohestani
AU  - Axel Gerdtsson
AU  - Dominik Glombik
AU  - Sinja Kristiansen
AU  - Mats Lambe
AU  - Jenny Magnusson
AU  - Per Nordlund
AU  - Erik Persson
AU  - Henrik Ugge
AU  - Peter Kirrander
PY  - 2026
DA  - 2026/11/05
JO  - BMJ Open
DO  - 10.1136/bmjopen-2026-122591
UR  - https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-122591
AB  - Purpose Penile Cancer Data Base Sweden (PenCBaSe) V.2.0 is an update of PenCBaSe V.1.0, which was established in 2013 to address a wide range of epidemiological research questions in a population-based cohort of men with penile cancer.The study population in PenCBaSe V.2.0 was defined by 3883 cases of penile intraepithelial neoplasia (PeIN) or penile cancer registered in the National Penile Cancer Register (NPECR).Participants PenCBaSe V.2.0 includes 3883 cases of PeIN or penile cancer registered in the NPECR between 2000 and 2023 and two separate comparison cohorts with 38 448 comparators free from PeIN or penile cancer matched on birth year, sex and region of residence. The median age at inclusion was 69 years (range 18–101).Findings to date The database contains register-based information collected from standardised forms in the NPECR on diagnostic evaluation, tumour characteristics, primary treatment, lymph node management, postoperative complications and follow-up with high completeness (95% between 2000 and 2023) and validity. Moreover, by means of record linkage to six national healthcare and sociodemographic registers, data on socioeconomic factors, comorbidity and patterns of filings of prescribed drugs are available. The comorbidity burden was lower in the comparison cohort.Future plans PenCBaSe V.2.0 will be used to investigate a multitude of research questions within three principal domains: socioeconomic status and demographic factors, risk factors for disease and stage, respectively treatment-related outcomes and complications. The steering committee of PenCBaSe welcomes new collaborations. For more information, please contact the chairman of the steering committee of PenCBaSe (https://cancercentrum.se/diagnosbehandling/cancerdiagnoser/penis/kvalitetsregister.3518.html).
SN  - 2044-6055
SN  - 2044-6055
ER  -